What is the recommended treatment approach for alcoholic liver disease, including management of severe alcoholic hepatitis?

Treatment of Alcoholic Liver Disease

Alcohol abstinence is the single most important treatment for all patients with alcoholic liver disease and must be the foundation of any management strategy. 1

General Management for All ALD Patients

Alcohol Cessation

• Mandatory for all patients - improves survival regardless of disease severity
• Pharmacologic options to maintain abstinence:
  • Baclofen and acamprosate are recommended 1
  • Naltrexone may be considered (though evidence in ALD is limited)
• Brief interventions should be implemented for hazardous drinkers 1
• Psychosocial support is essential

Nutritional Support

Active and aggressive nutritional therapy is critical as most ALD patients are malnourished 1:

• Target intake:
  • Protein: 1.2-1.5 g/kg/day (increase to 1.5 g/kg/day if critically ill)
  • Calories: 35-40 kcal/kg/day (increase to 40 kcal/kg/day if critically ill)
• If three meals daily are inadequate, add early morning and late-night meals 1
• Vitamin and mineral supplementation (especially in deficiency): vitamin A, thiamine, vitamin B12, folic acid, pyridoxine, vitamin D, and zinc 1
• Branched-chain amino acids may reduce hospitalizations for cirrhosis complications 1

Management of Severe Alcoholic Hepatitis

Defining Severe Disease

Use prognostic scores to identify patients requiring pharmacotherapy 2, 3:

• Modified Discriminant Function (mDF) ≥32 (primary criterion)
• MELD score >20-21
• Glasgow Alcoholic Hepatitis Score (GAHS) ≥9
• Presence of hepatic encephalopathy

Initial Assessment

Before initiating treatment 2, 3:

• Screen for infections: chest x-ray, blood cultures, urine cultures, ascitic fluid cultures
• Exclude contraindications:
  • Active uncontrolled infection
  • Gastrointestinal bleeding
  • Acute kidney injury with creatinine >2.5 mg/dL
  • Renal failure
  • Acute pancreatitis
  • Concomitant diseases (HBV, HCV, drug-induced liver injury, HCC)

First-Line Pharmacotherapy

For patients with mDF ≥32 and no contraindications, corticosteroids are the recommended first-line treatment 1:

• Prednisolone 40 mg/day orally for 28 days (or methylprednisolone 32 mg/day)
• Improves 28-day survival from 65% to 80-85% 1
• Can be stopped abruptly after 28 days or tapered over 2-3 weeks 3

Consider adding N-acetylcysteine to corticosteroids 1:

• Reduces 1-month mortality from 24% to 8% (though no long-term benefit)
• Decreases hepatorenal syndrome deaths from 22% to 9%
• Particularly useful for reducing short-term mortality

Monitoring Treatment Response

Assess response at day 7 using the Lille score 1, 3:

• Lille score <0.45: Continue prednisolone for full 28 days (responders)
• Lille score ≥0.45: Stop corticosteroids (non-responders)
• Lille score ≥0.56: Definite non-responders - discontinue immediately

Alternative scoring: Early change in bilirubin level (ECBL) - if bilirubin at day 7 is lower than day 1, continue treatment 1

Alternative Therapy

Pentoxifylline 400 mg orally three times daily for 4 weeks is an alternative when corticosteroids are contraindicated 1, 4:

• Improves survival primarily by reducing hepatorenal syndrome
• However, corticosteroids remain the preferred option - pentoxifylline was not statistically equivalent in head-to-head trials 1
• Do NOT use combination therapy with steroids and pentoxifylline - no survival benefit 1
• Do NOT switch to pentoxifylline in steroid non-responders - no benefit as rescue therapy 1

Therapies to AVOID

Anti-TNF-α agents are contraindicated 1:

• Infliximab: Higher mortality with combination therapy
• Etanercept: Higher 6-month mortality due to serious infections
• Both increase infection risk significantly

Nutritional Support in Severe AH

• Target >21 kcal/kg/day - patients achieving this have lower mortality regardless of other treatments 3
• Prefer oral route first, but use enteral feeding tube if oral intake inadequate 3
• Enteral nutrition alone may have comparable outcomes to corticosteroids in some studies 3
• Nearly half of patients cannot tolerate feeding tubes - monitor closely 3

Liver Transplantation

Indications for Transplant Evaluation

For decompensated cirrhosis 1:

• MELD score remains >17 after 3 months of abstinence
• Child-Turcotte-Pugh (CTP) class C patients benefit most from transplant
• CTP class A or B patients show no significant survival benefit

For severe alcoholic hepatitis 1:

• Consider early liver transplantation in highly selected patients with:
  • Lille score ≥0.45 (steroid non-responders)
  • No response to medical therapy
  • First episode of liver decompensation
  • Strong psychosocial support
• Survival rates comparable to or better than other indications for transplant

Important Caveats

• Traditional 6-month abstinence rule is being reconsidered for severe AH 1
• Recidivism rates post-transplant: 10-52% 1
• Requires careful psychological evaluation and long-term monitoring 1

Clinical Pitfalls to Avoid

1. Do not delay nutritional support - it reduces complications without additional risk 1
2. Do not use corticosteroids in patients with active infection - screen thoroughly first 2, 3
3. Do not continue steroids beyond day 7 in non-responders (Lille ≥0.45) - only exposes to side effects 1, 3
4. Do not use anti-TNF agents - they increase mortality 1
5. Monitor for acute kidney injury aggressively - avoid nephrotoxins, use albumin and vasoconstrictors early 2
6. Screen for infections repeatedly - 12-26% have infections at admission, up to 50% develop them on steroids 2

Long-Term Management

• Lifelong alcohol abstinence - 10-year survival is 88% with abstinence vs 73% with relapse 5
• Pharmacologic treatment of alcohol use disorder to maintain abstinence 6
• Management of cirrhosis complications (ascites, varices, encephalopathy)
• Ongoing transplant evaluation if MELD remains elevated 5
• Multidisciplinary care involving hepatology, addiction medicine, nutrition, and social work 2, 6